μ-Calpain is functionally required for α-processing of Alzheimer's β-amyloid precursor protein

被引:26
|
作者
Chen, M [1 ]
Fernandez, HL
机构
[1] Bay Pines VA Med Ctr, Neurobiol Aging Res Lab, Bay Pines, FL 33744 USA
[2] Bay Pines VA Med Ctr, Neurosci Res Lab, Bay Pines, FL 33744 USA
[3] Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA
关键词
Alzheimer; amyloid; calpain; siRNA;
D O I
10.1016/j.bbrc.2005.03.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's beta-amyloid precursor protein (APP) is normally processed by an unidentified alpha-secretase. A unique feature of this protease is its high sensitivity to phorbol esters, yet the mechanism involved is unclear. We have previously reported that phorbol 12,13-dibutyrate (PDBu) activates calpain, a Ca2+-dependent protease, and PDBu-induced release of APPs (secreted APP) is sensitive to calpain inhibitors, suggesting that calpain is involved in APP alpha-processing. In the present study, we found that PDBu markedly promoted the expression of both mu- and m-calpains in cultured fibroblasts. Dose-response and time course studies revealed that mu-calpain was more sensitive to PDBu than m-calpain and the temporal course of the mu-calpain change coincides better with that of APPs release. Moreover, the stimulatory effect of PDBu on p-calpain was selectively blocked by mu-calpain-specific siRNA (small interference RNA) and the blockage was accompanied by a concomitant decrease in APPs release. In contrast, m-calpain siRNA did not affect APPs release significantly. Measurement of amyloid beta protein (A beta) release in the mu-calpain siRNA-treated cells indicated that A beta 40 and A beta 42 levels inversely changed in relation to APPs, and the changes in A beta 42 were more prominent than in A beta 40. Together, these data suggest that calpain, particularly mu-calpain, is a potential candidate for alpha-secretase in the regulated APP alpha-processing, and that changes in this protease can affect the outcome of the overall APP processing. Published by Elsevier Inc.
引用
收藏
页码:714 / 721
页数:8
相关论文
共 50 条
  • [31] TDP-43 and amyloid precursor protein processing: implications for Alzheimer's disease
    Hicks, David A.
    [J]. NEURAL REGENERATION RESEARCH, 2021, 16 (07) : 1402 - 1403
  • [32] Processing of the Alzheimer's Disease beta A4 Amyloid Protein Precursor (APP)
    Younkin, Steven G.
    [J]. BRAIN PATHOLOGY, 1991, 1 (04) : 253 - 262
  • [33] A Model System to Study Intracellular Trafficking and Processing of the Alzheimer's Amyloid Precursor Protein
    da Cruz e Silva, Odete A. B.
    Vieira, Sandra Isabel
    Rebelo, Sandra
    da Cruz e Silva, Edgar F.
    [J]. NEURODEGENERATIVE DISEASES, 2004, 1 (4-5) : 196 - 204
  • [34] The effect of simvastatin treatment the processing of the amyloid precursor protein in patients with Alzheimer's disease
    Hoglund, K
    Thelen, KM
    Syversen, S
    Sjogren, M
    von Bergmann, K
    Wallin, A
    Vanmechelen, E
    Vanderstichele, H
    Luetjohann, D
    Blennow, K
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S584 - S584
  • [35] TDP-43 and amyloid precursor protein processing: implications for Alzheimer's disease
    David A.Hicks
    [J]. Neural Regeneration Research, 2021, 16 (07) : 1402 - 1403
  • [37] Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease
    Ling, Y
    Morgan, K
    Kalsheker, N
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (11): : 1505 - 1535
  • [38] Vasopressin and Bradykinin Regulate Secretory Processing of the Amyloid Protein Precursor of Alzheimer's Disease
    Roger M. Nitsch
    Cindy Kim
    John H. Growdon
    [J]. Neurochemical Research, 1998, 23 : 807 - 814
  • [39] Vasopressin and bradykinin regulate secretory processing of the amyloid protein precursor of Alzheimer's disease
    Nitsch, RM
    Kim, C
    Growdon, JH
    [J]. NEUROCHEMICAL RESEARCH, 1998, 23 (05) : 807 - 814
  • [40] Amyloid precursor protein mRNAs in Alzheimer's disease
    Harrison, PJ
    WightonBenn, WH
    Heffernan, JM
    Sanders, MW
    Pearson, RCA
    [J]. NEURODEGENERATION, 1996, 5 (04): : 409 - 415